Radiation Oncology

Lung Cancer

Appointment New Patient Appointment or 214-645-8300

UT Southwestern Medical Center’s lung cancer program includes a dedicated team that offers a level of expertise unmatched in Dallas and North Texas. We provide our patients with comprehensive, timely, and effective care.

Some of the most groundbreaking achievements in radiation therapy for lung cancer in the past decade have taken place at UT Southwestern. Our physicians have pioneered the use of stereotactic radiation to treat early-stage lung cancer, in some instances changing the medical standard of care for certain patient populations. 

Meet Our Team

Shahed Badiyan, M.D.

Shahed Badiyan, M.D.

Anundip Gill, M.S.N., APRN, FNP-C

Anundip Gill, M.S.N., APRN, FNP-C

Kenneth Westover, M.D., Ph.D.

Kenneth Westover, M.D., Ph.D.

Yuanyuan Faith Zhang, M.D., Ph.D.

Yuanyuan Faith Zhang, M.D., Ph.D.

Educational Materials

Lung Clinical Trials

As one of the top academic medical centers in the country and the only National Cancer Institute-designated cancer center in North Texas, we lead and participate in a number of clinical trials aimed at improving the outcomes of patients with cancer. The Department of Radiation Oncology enrolls approximately 200 new patients in clinical trials each year. 

Clinical trials are critical in developing new therapies for cancer and can mean having access to new medication, groundbreaking research, and additional clinical care. Our clinical trials team is comprised of radiation oncologists, radiation biologists, clinical research coordinators, quality assurance coordinators, and clinical data specialists. 


Non-Small Cell Cancer

  • Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Cancer (NSCLC): A Randomized Phase II/III Trial (STU 042017-024: NRG-LU002). Learn more.
  • A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC), the STABLE-MATES Trial (STU 022015-069: JoLT-Ca)
  • A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-Small Cell Lung Cancer (STU 2019-0858: PACIFIC 4/RTOG-3515)
  • A Phase I/II Study of Stereotactic Body Radiation Therapy (SBRT) with or without GC4711 for Early Stage, Centrally Located or Large Non-Small Cell Lung Cancer (NSCLC). (STU 2019-1764)

Cancer Cachexia

  • A Pilot Study of Ruxolitinib in the Treatment of Cancer Cachexia. (STU 2021-0475)


  • Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereotactic Ablative Body Radiotherapy (STU 062016-073: Lung SAbR)
  • Tissue Procurement and Outcome Collection for Cancer Patients With and Without Cachexia (STU 2019-1390)

If you’re interested in a clinical trial, please talk to your doctor.

Learn more about clinical trials.

Helpful Resources